期刊文献+

促黑素对小鼠成骨细胞OPG/RANKLmRNA表达的影响 被引量:2

Effect of α-melanocyte stimulating hormone on the expressions of OPG and RANKL mRNA in mouse osteoblasts
原文传递
导出
摘要 目的探讨原代培养的小鼠成骨细胞黑皮质素受体(MCR)表达的种类及促黑素(α-MSH)对其骨保护素(OPG)和核因子-κB受体活化因子配体(RANKL)mRNA表达的影响。方法酶消化法分离3 d内新生C57BL/6小鼠原代成骨细胞,培养液中分别加入10-7、10-8和10-9mol/L的α-MSH培养12 h,作为A、B、C组;培养液中加入10-7mol/Lα-MSH,分别培养6、12、24 h,作为D、E、F组。对照组正常培养。采用实时定量PCR方法分析α-MSH对成骨细胞OPG/RANKL mRNA表达的影响。利用RT-PCR法测定原代成骨细胞MCR的表达。结果小鼠原代成骨细胞表达MC1R、MC2R、MC4R和MC5R;与对照组相比,α-MSH促进OPG/RANKL mRNA的表达(P<0.05)。结论α-MSH可能通过MCR系统促进小鼠原代成骨细胞OPG/RANKL mRNA的表达。 Objective To investigate the types of melanocortin receptor (MCR) of the primary osteoblasts, and the effect of α-melanocyte stimulating hormone (ct-MSH) on the expressions of osteoprotegerin (OPG) and receptor activator of nuclear factor-kappa B ligand (RANKL) mRNA in mouse osteoblasts. Methods Calvarial osteoblasts were separated and cultured in vitro by the mechanical separation and enzyme digestion method. The primary osteoblasts were divided into groups A, B and C, which were treated with 10^-7, 10^-8 and 10^-9 mol/L et-MSH respectively for 12 h; the primary osteoblasts were divided into groups D, E and F, which were treated with 10^-7 mol/L α-MSH for 6, 12 and 24 h respectively. Control group was set up at the same time. The expressions of OPG and RANKL mRNA were detected by Real-Time PCR. MCR subtypes in the primary osteoblasts were measured by RT-PCR. Results MC1R, MC2R, MC4R and MC5R were expressed in primary cultured osteoblasts. The expressions of OPG and RANKL mRNA significantly increased after incubation with α-MSH (P 〈 0.05). Conclusion α-MSH might promote the expressions of OPG and RANKL mRNA in the primary osteoblasts through MCR system.
出处 《山东大学学报(医学版)》 CAS 北大核心 2014年第3期56-58,63,共4页 Journal of Shandong University:Health Sciences
基金 国家自然科学基金(30660070) 山东省中青年科学家科研奖励基金(BS2010YY002)
关键词 促黑素 骨保护素 核因子ΚB受体活化因子配体 黑皮质素受体 α-melanocyte stimulating hormone Osteoprotegerin Recetor activator nuclear factor-kappa B ligand Melanocortin receptor
  • 相关文献

参考文献17

  • 1Horowitz M C, Xi Y, Wilson K, et al. Control of oste- oclastogenesis and bone resorption by members of the TNF family of receptors and ligands[ J]. Cytokine Growth Factor Rev, 2001, 12( 1 ) :9-18.
  • 2原发性骨质疏松症诊治指南(2011年)[J].中华骨质疏松和骨矿盐疾病杂志,2011,4(1):2-17. 被引量:1842
  • 3中国健康促进基金会骨质疏松防治中国白皮书编委会.骨质疏松症中国白皮书.中华健康管理学杂志,2009,3(3):148-156.
  • 4Trouvin A P, Gob V. Receptor activator of nuclear fac- tor-KB ligand and osteoprotegerin : maintaining the balance to prevent bone loss [ J]. Clin Interv Aging, 2010, 5 : 345 -354.
  • 5Kostenuik P L, Shalhoub V. Osteoprotegerin:a physio- logical and pharmacological inhibitor of bone resorption [J]. Curr Pharm Des, 2001, 7(8) :613-635.
  • 6Brzoska T, Luger T A, Maaser C, et al. Alpha-melano- cyte-stimulating hormone and related tripeptides:biochem- istry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of im- mune-mediated inflammatory diseases EJ ]. Endocr Rev, 2008, 29(5):581-602.
  • 7Diano S. New aspects of melanocortin signaling: a role for PRCP in ct-MSH degradation [J]. Front Neuroendocrinol, 2011, 32( 1 ) :70-83.
  • 8Eves P C , Haycock J W. Melanocortin signalling mecha- nisms[J]. Adv Exp Med Biol, 2010, 681:19-28.
  • 9Cornish J, Callon K E, Mountjoy K G, et al. alpha-mel- anocyte-stimulating hormone is a novel regulator of bone [J]. Am J Physiol Endocrinol Metab, 2003, 284 (6) : E1181-1190.
  • 10Dores R M, Baron A J. Evolution of POMC: origin, phylogeny, posttranslational processing, and the melano- cortins[J]. Ann N Acad Sci, 2011, 1220:34-48.

共引文献1912

同被引文献17

  • 1熊茜,张秀珍.17β-雌二醇对新生大鼠成骨细胞护骨素和破骨细胞分化因子表达的调节[J].中华内分泌代谢杂志,2007,23(3):224-225. 被引量:7
  • 2Takashi Ito, Stephen WS, Junichi A, et al. The potential usefulness [ of taurine on diabetes menitus and its complications [J]. Amino Acids, 2012, 42(5): 1529-1539.
  • 3No authors listed. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group[J]. World Health Organ Tech Rep Ser, 1994, 843: 1-129.
  • 4Srivas tava AK, Macfarlane G, Srivas tava VP, et al. A new monoclonal antibody ELISA for detection and characterization of C-telopeptide fragments of type I collagen in urine[J]. Calcif Tissue Int, 2001, 69 (6) : 327-336.
  • 5Filip RS, Zagorski J. Age and BMD related differences in biochemical markers of bone metabolism in rural and urban women from Lublin Region, Poland[J]. Ann Agric Environ Med, 2004, 11(2): 255-259.
  • 6Szulc P, Garnero P, Munoz F, et al. Cross-sectional evaluation of bone metabolism in men[J]. J Bone Miner Res, 2001, 16(9): 1642-1650.
  • 7Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density[J]. Cell, 1997, 89(2): 309-319.
  • 8Armstrong AP1, Tometsko ME, Glaccum M, et al. A RANK/ TRAF6-dependent signal transduction pathway is essential for osteoclast cytoskeletal organization and resorptive function [J]. J Biol Chem~ 2002, 277(46): 44347-44356.
  • 9Wang Q P, Li XP, Wang M, et al. Adiponectin exerts its negative effect on bone metabolism via OPG/RANKL pathway: an in vivo study[J]. Endocrine, 2014, 47(3): 845-853.
  • 10Inanc M, Kaynar L, Enhos S, et al. Nuclear factor-kappa B ligand and osteoprotegerin levels in serum and gingival crevicular fluid in patients with bone metastases treated with zoledronic acid[J]. Med Oncol, 2014, 31(3): 837.

引证文献2

二级引证文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部